RxDoctor Payments Data

Tamas Soos, MD

Geriatric Medicine · Elkin, NCNPI 1700858404

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Organogenesis Inc. accounts for 76.3% of it on its own, with 6 other manufacturers making up the rest. 2023 is the largest year on record at $386, 4.8 times the $81 reported in 2019.

$578in general payments, 2019–2025

Across 64 payments — averaging $9.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$441
  • Sunovion Pharmaceuticals Inc.$54
  • Averitas Pharma Inc.$25
  • Paratek Pharmaceuticals, Inc.$17
  • Johnson & Johnson$15
  • Kerecis Limited$13
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$578100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$578 in reported general payments places this provider in the 80th percentile of 138 geriatric medicine providers in North Carolina.

See all geriatric medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$356,156
Medicare patients
145
Services billed
3,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban710$114,511
XifaxanRifaximin15$45,219
VraylarCariprazine Hcl82$31,090
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$25,660
ZenpepLipase/Protease/Amylase52$19,948
XareltoRivaroxaban118$19,646
ErtapenemErtapenem Sodium48$16,170
Potassium Chloride969$10,767
SantylCollagenase Clostridium Hist.29$9,657
JardianceEmpagliflozin55$9,439
Levetiracetam462$7,940
Tamsulosin Hcl730$7,705
Atorvastatin Calcium927$7,594
Memantine Hcl433$7,453
MyrbetriqMirabegron60$7,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$15$19,646118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 138 geriatric medicine providers in North Carolina.

Other geriatric medicine in Elkin

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →